Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment, YEARS Algorithm for Diagnosis of PE in Patients With Cancer, HPV Screening and Self-Collected Vaginal Samples, and more
Summary
Hosted by JAMA editors Kirsten Bibbins-Domingo and Preeti Malani, this episode reviews recent clinical research. Key topics include using the YEARS algorithm to safely reduce CT scans in cancer patients with suspected pulmonary embolism. The discussion also covers negative trials for Alzheimer’s treatments, new diagnostic biomarkers, Medicaid drug pricing reforms, and guidelines for hip fracture management and HPV screening.
Topics discussed
Introduction to Healthy Dialogue and JAMA Editor's Summary
YEARS algorithm to avoid CT scans in cancer patients with suspected PE
Failed trial of OGA inhibitor separognostat for Alzheimer's disease
Meta-analysis on centeloid cutoffs for amyloid PET scans
Plasma P-tau-217 as a predictor of cognitive impairment risk
Case study on amyloid clearance patterns after aducanumab treatment
Medicaid generous payment model and prescription drug cost savings
Viewpoints on Medicaid cuts and Supreme Court medical standards
JAMA guide to difference-in-difference statistical analysis
JAMA review on hip fracture management and prevention in older adults
Clinical guideline on self-collected vaginal samples for HPV screening
Pre-pregnancy care recommendations and episode conclusion
Listen ad-free on Castria